Shigella WRSS1 Vaccine Trial in Bangladesh

Inclusion Criteria

• Male or female children aged between 12 to 24 month of age at the time of vaccination
• General good health as determined by the screening evaluation no greater than 30 days before admission
• Father, mother or other legally acceptable representative (guardian) properly informed about the study, able to understand it and sign the informed consent form
• Normal bowel habits (< 3 grade 1 or 2 stools each day; ≥ 1 grade 1 or 2 stools every 2 days)
• Free of obvious health problems as established by medical history and clinical examination before entering into the study.
• Parent or guardian available for the entire period of the study and reachable by study staff throughout the entire follow-up period.
• Signed Informed Consent from the Parent or legal guardian

Exclusion Criteria

• Presence of a significant medical that in the opinion of the Investigator precludes participation in the study
• Known infection with human immunodeficiency virus (HIV)
• Presence in the serum of hepatitis A virus (HAV) or hepatitis C virus (HCV) antibody.
• History of congenital abdominal disorders, intussusception, abdominal surgery or any other congenital disorder.
• Participation in research involving another investigational product (defined as receipt of investigational product) 30 days before planned date of first vaccination or concurrently participating in another clinical study, at any time during the study period, in which the child has been or will be exposed to an investigational or a non-investigational product
• Clinically significant abnormalities on physical examination
• Clinically significant abnormalities in screening hematology, serum chemistry as determined by the PI or the PI in consultation with the Study Physician
• History of febrile illness within 48 hours prior to vaccination
• Known or suspected impairment of immunological function based on medical history and physical examination
• Prior receipt of any Shigella vaccine
• Fever at the time of immunization. Fever is defined as a temperature ≥ 37.5C (99.5F) on axillary, oral, or tympanic measurement
• History of known shigellosis, chronic diarrhea/dysentery in the past 2 months
• Current use of iron or zinc supplements within the past 7 days; current use of antacids (H2 blockers, omeprazol, OTC agents) or immunosuppressive drug
• Allergy to quinolone, sulfa, and penicillin classes of antibiotics
• Clinical evidence of active gastrointestinal illness
• Prior receipt of a blood transfusion or blood products, including immunoglobulins
• Presence of any significant systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, cancer or autoimmune disease) as determined by medical history and/or physical examination which would endanger the participant's health or is likely to result in non-conformance to the protocol.
• History of any neurologic disorders or seizures.
• Acute disease at the time of enrolment
• Medically significant malnutrition, defined as moderate malnutrition (wt-for-age z-score between -3.0 and -2.0) and severe malnutrition (wt-for-age z-score <-3.0 or edema)
• Any conditions which, in the opinion of the investigator, might jeopardize the safety of study participants or interfere with the evaluation of the study objectives
• Receipt of antimicrobial drugs for any reason or a fever ≥ 38C within 7 days before vaccination
• History of diarrhea during the 7 days before vaccination.
• Has any household member(s) who is immunocompromised or under the age of 1 year old.
• Culture or polymerase chain reaction (PCR) positive for any Shigella strain